Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
Primary Purpose
Stroke, Acute, Ischemic Attack, Transient
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Sanchitongshu
placebo of Sanchitongshu
Aspirin
Clopidogrel
placebo of clopidogrel
Sponsored by
About this trial
This is an interventional prevention trial for Stroke, Acute focused on measuring Sanchitongshu, Acute Minor Stroke, Transient Ischemic Attack
Eligibility Criteria
Inclusion Criteria:
- age of 40 years to 80 years
- diagnosis of an acute minor ischemic stroke or transient ischemic attack; and ability to start the study drug within 24 hours after symptom onset, which was defined as the point at which the patient reported no longer being in a normal condition. Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale(NIHSS). TIA was defined as focal brain ischemia with resolution of symptoms within 24 hours after onset plus a moderate-to-high risk of stroke recurrence(defined as a score≥4 at the time of randomization on the ABCD2). All patients were confirmed by brain CT or MRI.
- Patients had ability to accept the medicine and rules of the research.
- Patients had no serious complications and had normal renal function and liver function.
Exclusion Criteria:
- age younger than 40 and older than 80
- Patients need thrombolysis
- hemorrhage; other conditions, such as vascular malformation, tumor, abcess, or other major nonischemic brain disease
- isolated sensory symptoms(e.g., numbness), isolated visual changes, or isolated dizziness or vertigo without evidence of acute infarction on baseline CT or MRI of the head
- a score of more than 2 on the modified Rankin scale(scores ranges from 0(no symptoms) to 6(death))immediately before the occurrence of the index ischemic stroke or TIA, indicating moderate disability or worse at baseline
- TIA or minor stroke caused by angiography or surgery
- a clear indication for anticoagulation therapy(presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardio valve)
- anticipated requirement for long-term nonstudy antiplatelet drugs or for non steroidal antiinflammatory drugs affecting platelet function
- accompanied with severe disorders of heart, liver, and kidney
- severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months.
- history of hemorrhage or bleeding tendency of other system( such as thrombocytopenic purpura)
- gastrointestinal bleeding or major surgery within the previous 3 months
- planned or probable revascularization(any angioplasty or vascular surgery)within 3 months after.Operation or Interventional Therapy require discontinuation of study drug
- Aspirin, clopidogrel or notoginseng allergy
- a history of alcoholism or drug abuse in past 12 months
- pregnant and lactating women, or women of childbearing age without taking any effective contraceptive measures
- patients have other serious disease or abnormal laboratory results that is unfavorable to join the research
- patients receiving other investigational drugs or devices
- incomprehension of the character and category of the research and unable to follow the research plan
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Sanchitongshu & placebo of lopidogrel
placebo of Sanchitongshu & lopidogrel
Arm Description
sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
Outcomes
Primary Outcome Measures
Percentage of patients with the180-day new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage)
Secondary Outcome Measures
Percentage of patients with the 180-day new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually
Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 180 days follow-up
Further efficacy exploratory analysis:Impairment (changes in NIHSS scores at 180 days follow-up)
Further efficacy exploratory analysis:Impairment (changes in Barthel Index at 180 days follow-up)
Further efficacy exploratory analysis: stroke impact scale
Efficacy endpoint will also be analyzed stratified by etiological subtypes
death from any cause
Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage.
Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 180 days
Incidence Intracranial hemorrhage events at 180 days
Full Information
NCT ID
NCT02975076
First Posted
November 18, 2016
Last Updated
November 22, 2016
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02975076
Brief Title
Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
Official Title
Radix/Rhizoma Notoginseng Extract (Sanchitongtshu) Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Placebo-controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
December 2016 (undefined)
Primary Completion Date
November 2019 (Anticipated)
Study Completion Date
November 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Agents of sanchi have been widely used as a complementary medicine for stroke in China. Sanchitongshu is a new Chinese patent medicine extracted from sanchi which has stronger anti-platelet activity than other agents of sanchi. The investigators's aim was to investigate the synergistic action of aspirin combined with sanchitongshu capsule in the treatment of patients with minor ischemic stroke and transient ischemic attack.
Detailed Description
Transient ischemic attack (TIA) and acute minor ischemic stroke are common and often lead to disabling events. In China, there are approximately 3 million new strokes every year, and approximately 30% of them are minor ischemic strokes. The incidence of TIA in China has not been determined, but on the basis of the incidence in other countries, there are probably more than 2 million TIAs annually in China. The risk of another stroke occurring after a TIA or minor stroke is high, with approximately 10 to 20% of patients having a stroke within 3 months after the index event; most of these strokes occur within the first 2 days. The role of antiplatelet therapy for secondary stroke prevention has been well established.
As yet, aspirin is the only antiplatelet agent that has been studied in the acute phase of stroke, during which its benefit is modest. Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial shows that among patients with high-risk TIA or minor ischemic stroke who are initially seen within 24 hours after symptom onset, treatment with clopidogrel plus aspirin for 21 days, followed by clopidogrel alone for a total of 90 days, is superior to aspirin alone in reducing the risk of subsequent stroke events. The combination of clopidogrel with aspirin did not cause more hemorrhagic events in this patient population than aspirin alone. The analytical results provided basis for the synergistical effect of Aspirin and clopidogrel in inhibiting platelet aggregation. However, long term use of clopidogrel bring people financial burden so that the patients have less compliance of medication. Therefore, the investigators need to explore new treatment for more effective, safe and economic.
Sanchi is one of the most widely used herbal medicine in China for ischemic stroke, of which panax notoginseng saponins (PNS) are the main active components. Previously there were lots of clinical trials on agents of PNS for ischemic stroke in China and had positive results. Sanchitongshu capsule is a new Chinese patent medicine extracted from sanchi. 80% of the ingredients in sanchi-tongshu capsule are panaxatriol saponins (PTS) and 60% of PTS are Rg1 which has strongest anti-platelet activity of all the PNS. PTS were proven by experiment and phase III clinical trials to have antithrombosis effect through mechanisms of inhibiting platelet aggregation, decreasing blood viscosity, strengthening activities of fibrinolysis system, and promoting vascular endothelial NO releasing. More recent experimental studies indicated anti-inflammatory and neuroprotective effect of PTS. Compared with other agents of Sanchi, Sanchitongshu capsule contains higher purity of PTS and Rg1. Thus, Sanchitongshu capsule theoretically should be vigorous in improving ischemic status after ischemic stroke.
Include, the investigators will investigate the synergistic action of aspirin combined with sanchitongshu capsule in the treatment of patients with minor ischemic stroke and transient ischemic attack.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute, Ischemic Attack, Transient
Keywords
Sanchitongshu, Acute Minor Stroke, Transient Ischemic Attack
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sanchitongshu & placebo of lopidogrel
Arm Type
Experimental
Arm Description
sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
Arm Title
placebo of Sanchitongshu & lopidogrel
Arm Type
Placebo Comparator
Arm Description
placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
Intervention Type
Drug
Intervention Name(s)
Sanchitongshu
Other Intervention Name(s)
Radix/Rhizoma Notoginseng extract
Intervention Description
The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
Intervention Type
Drug
Intervention Name(s)
placebo of Sanchitongshu
Intervention Description
The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
Intervention Type
Drug
Intervention Name(s)
Aspirin
Other Intervention Name(s)
Aspirin Enteric-coated Tablets
Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Other Intervention Name(s)
Clopidogrel Bisulfate
Intervention Type
Drug
Intervention Name(s)
placebo of clopidogrel
Primary Outcome Measure Information:
Title
Percentage of patients with the180-day new vascular events, defined as any event of the following: Any stroke (ischemic or hemorrhage)
Time Frame
180 days
Secondary Outcome Measure Information:
Title
Percentage of patients with the 180-day new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ TIA/ MI/ vascular death) as a cluster and evaluated individually
Time Frame
180 days
Title
Modified Rankin Scale score changes (continuous) and dichotomized at percentage with score 0-2 vs. 3-6 at 180 days follow-up
Time Frame
180 days
Title
Further efficacy exploratory analysis:Impairment (changes in NIHSS scores at 180 days follow-up)
Time Frame
180 days
Title
Further efficacy exploratory analysis:Impairment (changes in Barthel Index at 180 days follow-up)
Time Frame
180 days
Title
Further efficacy exploratory analysis: stroke impact scale
Time Frame
180 days
Title
Efficacy endpoint will also be analyzed stratified by etiological subtypes
Time Frame
180 days
Title
death from any cause
Time Frame
180 days
Title
Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage.
Time Frame
180 days
Title
Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 180 days
Time Frame
180 days
Title
Incidence Intracranial hemorrhage events at 180 days
Time Frame
180 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age of 40 years to 80 years
diagnosis of an acute minor ischemic stroke or transient ischemic attack; and ability to start the study drug within 24 hours after symptom onset, which was defined as the point at which the patient reported no longer being in a normal condition. Acute minor stroke was defined by a score of 3 or less at the time of randomization on the National Institutes of Health Stroke Scale(NIHSS). TIA was defined as focal brain ischemia with resolution of symptoms within 24 hours after onset plus a moderate-to-high risk of stroke recurrence(defined as a score≥4 at the time of randomization on the ABCD2). All patients were confirmed by brain CT or MRI.
Patients had ability to accept the medicine and rules of the research.
Patients had no serious complications and had normal renal function and liver function.
Exclusion Criteria:
age younger than 40 and older than 80
Patients need thrombolysis
hemorrhage; other conditions, such as vascular malformation, tumor, abcess, or other major nonischemic brain disease
isolated sensory symptoms(e.g., numbness), isolated visual changes, or isolated dizziness or vertigo without evidence of acute infarction on baseline CT or MRI of the head
a score of more than 2 on the modified Rankin scale(scores ranges from 0(no symptoms) to 6(death))immediately before the occurrence of the index ischemic stroke or TIA, indicating moderate disability or worse at baseline
TIA or minor stroke caused by angiography or surgery
a clear indication for anticoagulation therapy(presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardio valve)
anticipated requirement for long-term nonstudy antiplatelet drugs or for non steroidal antiinflammatory drugs affecting platelet function
accompanied with severe disorders of heart, liver, and kidney
severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months.
history of hemorrhage or bleeding tendency of other system( such as thrombocytopenic purpura)
gastrointestinal bleeding or major surgery within the previous 3 months
planned or probable revascularization(any angioplasty or vascular surgery)within 3 months after.Operation or Interventional Therapy require discontinuation of study drug
Aspirin, clopidogrel or notoginseng allergy
a history of alcoholism or drug abuse in past 12 months
pregnant and lactating women, or women of childbearing age without taking any effective contraceptive measures
patients have other serious disease or abnormal laboratory results that is unfavorable to join the research
patients receiving other investigational drugs or devices
incomprehension of the character and category of the research and unable to follow the research plan
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaorong Wang, Master
Phone
13621712767
Email
wangxr_mail@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Fei Lu
Phone
021-25076146
Email
xinhuakeyan@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xinhua Hospital
Organizational Affiliation
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
We'll reach out to this number within 24 hrs